Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:

NCT ID: NCT05305768 Not yet recruiting - Clinical trials for Glabellar Frown Lines

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

Start date: May 1, 2022
Phase: Early Phase 1
Study type: Interventional

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Xeomin in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

NCT ID: NCT05277337 Completed - Clinical trials for Glabellar Frown Lines

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

STAR
Start date: February 4, 2022
Phase: Phase 4
Study type: Interventional

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

NCT ID: NCT05217355 Completed - Clinical trials for Glabellar Frown Lines

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.

NCT ID: NCT05148000 Completed - Clinical trials for Glabellar Frown Lines

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

This study to assess aesthetic improvement following treatment with QM1114-DP.

NCT ID: NCT05146999 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Start date: May 9, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines

NCT ID: NCT05129319 Completed - Clinical trials for Glabellar Frown Lines

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Start date: December 16, 2021
Phase: Early Phase 1
Study type: Interventional

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

NCT ID: NCT05083286 Recruiting - Clinical trials for Glabellar Frown Lines

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Start date: October 20, 2021
Phase: Early Phase 1
Study type: Interventional

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

NCT ID: NCT05059587 Completed - Clinical trials for Glabellar Frown Lines

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Start date: August 30, 2021
Phase: Phase 3
Study type: Interventional

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.

NCT ID: NCT04996810 Completed - Clinical trials for Glabellar Frown Lines

The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. Safety is assessed after 12 weeks. In Phase II, subjects with moderate to severe glabellar lines are enrolled and will be injected the "PROTOXIN" or the "BOTOX®" at a total of 20U(4U/0.1mL each)in five sites of the glabellar lines. Thereafter, efficacy and safety are assessed by comparing with BOTOX®.

NCT ID: NCT04830345 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Start date: June 29, 2020
Phase: Phase 3
Study type: Interventional

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.